KB-1210

Romosozumab

52674

Home » Romosozumab

Background of Romosozumab

Romosozumab is a humanized monoclonal antibody used for treating osteoporosis in postmenopausal women who are at a high risk of fracture, as well as in patients who have not responded to other therapies or cannot tolerate them. This medication works by preventing bone resorption and promoting bone formation. However, it is important to note that a study has found an association between Romosozumab and an elevated risk of cardiac death, heart attack, and stroke.

Specifications

Catalog Number	KB-1210
Antibody Name	Romosozumab
Isotype	Human IgG2,kappa
FC Muations	Wild Type
Target	SOST
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014;370:412-420.
Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26:19-26